Tag:
Durect
Latest Headlines
Latest Headlines
Takeda abandons Euro rights to Durect's controlled-release pain drug
For the second time this year, Durect ($DRRX) faces a setback over its controlled-release anti-pain drug Posidur. The Cupertino, CA-based company disclosed that its European development and marketing
Durect shares nosedive on Phase III upset
Durect ( $DRRX ) disappointed investors with data from a Phase III study of anti-pain drug Posidur that were revealed Thursday, and the developer's share price was down more than 30% as of late this
Durect, Zogenix in deal for drug that could rival major J&J treatment
Durect has bounced back some from a regulatory setback last month with a brand new pact with developer Zogenix. The two companies struck a deal to develop a long-acting version of the antipsychotic
Durect's pain drug fails to clear key hurdle in PhIIb
Just days after signing a $212.5 million U.S. licensing deal with Hospira , Durect (DRRX) reports that its pain drug Posidur--a long-acting version of the anesthetic bupivacaine--equaled an injectable
